Firma GILUPI, Autor bei Presse-Blog

Quantification and phenotyping of circulating tumor cells isolated with the GILUPI CellCollector® technology

13. Juli 2018 Firma GILUPIMedizintechnikcancer, cellcollector, circulating tumor cells, Gilupi, isolation, medical wire, patients, study, tumor

GILUPI announces the release of a video article presenting an innovative approach for isolation of circulating tumor cells (CTCs) by the use of the GILUPI CellCollector® and their downstream phenotyping in combination with chromosomal rearrangement detection [1]. CTCs can often be Mehr

GILUPI attends the ISMRC congress in Montpellier, France

3. Mai 2018 Firma GILUPIMedizintechnikbiopsy, cancer, cellcollector, cells, clinical, congress, CTCs, Gilupi, jurinke, patients, presentation, study, therapy, tumor, with

GILUPI GmbH is pleased to announce its participation at the 2018 ISMRC (International Symposium on Minimal Residual Cancer) congress. The 11th ISMRC symposium will take place from 3rd to 5th of May in Montpellier, France and is focused on “Minimal Mehr

GILUPI extends Patent Portfolio – New European Patent granted

18. April 2018 Firma GILUPIMedizintechnikcell, Circulating tumor cell, european patent, Gilupi, jurinke, medical, patent

GILUPI GmbH announced that the company was granted a European patent protecting the unique and innovative GILUPI technology for the capture of circulating cancer cells (CTCs) and further applications. The European Patent Office (EPO) issued patent EP2807979 B1 entitled “Detection Mehr

New study extends application range of GILUPI CellCollector® towards quantitative analysis of gene expression in circulating tumor cells

20. Februar 2018 Firma GILUPIMedizintechnikcancer, cellcollector, circulating tumor cells, clinical, CTCs, Gilupi, kras, medical, new, pancreatic cancer patient, patients, prostate cancer, PSA, study, tumor

GILUPI announces the publication of a peer reviewed study about a new and promising mRNA-based assay that allows detection and quantification of clinically relevant prostate and pancreas cancer markers in circulating tumor cells (CTCs)[1]. CTCs are a surrogate marker for Mehr

Appointment of Dr. Christian Jurinke as CEO completes Management Team of GILUPI

18. Januar 2018 Firma GILUPIMedizintechnikAlexander Herrmann, cancer, ceo, Christian Jurinke, Gilupi, management, manager

GILUPI GmbH announces that Dr. Christian Jurinke is appointed to the position of CEO and together with Alexander Herrmann is now managing the company. Alexander Herrmann, Managing Director of GILUPI, stated „Dr. Jurinke is an accomplished expert when it comes Mehr

Molecular Characterization of Circulating Tumor Cells isolated with GILUPI Technology from Prostate Cancer Patients

14. Dezember 2017 Firma GILUPIMedizintechnikcancer, cellcollector, circulating tumor cells, Gilupi, patients, pcr, promising, prostate, research, rna, Studie, study, technology, treatment, tumor

GILUPI GmbH announces the recent publication of a clinical study demonstrating multiplex gene expression profiling of circulating tumor cells (CTCs) isolated in vivo from high-risk prostate cancer patients by the use of GILUPI CellCollector® [1]. Prostate cancer is a very Mehr

Early lung cancer screening with CTC detection using the GILUPI CellCollector® and Low-Dose Computed Tomography

1. November 2017 Firma GILUPIMedizintechnikcancer, cellcollector, china, clinician, CTCs, disease, Gilupi, lung, next generation sequencing, patients, screening, sequencing, study, tumor

GILUPI GmbH announces the release of a scientific article about the detection of circulating tumor cells (CTCs) from blood of different groups of pulmonary disease patients by the use of GILUPI CellCollector® [1]. Lung cancer is worldwide the most common Mehr

GILUPI will attend at the ACTC congress in Rhodes

21. September 201726. September 2017 Firma GILUPIMedizintechnik.doctor, ACTC, cancer, cellcollector, clinical, congress, ctc, ctdna, Gilupi, liquid biopsy, lung, lung cancer, nsclc, patients, study

GILUPI GmbH is pleased to announce its participation at the 2017 ACTC (Advances in Circulating Tumor Cells) congress. The 3rd ACTC meeting will take place from 4th to 7th October in Rhodes, Greece and is focused on “Liquid Biopsy in Mehr

In vivo detection of CTCs in head and neck cancer patients using the GILUPI CellCollector®

6. September 2017 Firma GILUPIMedizintechnikcancer, cellcollector, cells, ctc, disease, Gilupi, head and neck, patients, prognosis, study, tumor

GILUPI GmbH announces the recent publication of a clinical study demonstrates the isolation of circulating tumor cells (CTCs) from blood of squamous cell carcinoma of head and neck (SCCHN) patients with the GILUPI CellCollector® [1]. Isolating and analyzing CTCs from Mehr

Autor: Firma GILUPI